Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00572455 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 318
- Enrollment target
NCT00572455: Completed Phase 2 study, sponsored by Pfizer.
NCT00572455 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 318 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (139% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00572455, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 318 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of PF-04217329.
Primary Outcome
Diurnal IOP was defined as the mean IOP over 24 hours. IOP was measured using Goldmann applanation tonometer. IOP was measured in both the eyes, and the eye with higher IOP reading at the 2 eligibility visits was referred as 'study eye' for efficacy assessment. If both the measurements were equal, right eye was selected as the study eye. IOP was measured twice in the same eye, and if the difference between 2 measurements was less than or equal to 2 millimeter of mercury (mmHg), the mean of the 2
Interventions
- DRUG PF-04217329 - Lowest Dose
- DRUG PF-04217329 - Low Dose
- DRUG PF-04217329 - Middle Dose
- DRUG PF-04217329 - High Middle Dose
- DRUG PF-04217329 - High Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 318 participants |
| Start Date | 2007-12-11 |
| Est. Completion | 2009-06-26 |
| Phase | Phase 2 |
What the finished NCT00572455 record still lists
NCT00572455 is an interventional study that assigns participants to a tested intervention. The registered 318 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (139% higher).
The record links to 0 conditions, and to 5 interventions - of which PF-04217329 - Lowest Dose is the first listed.
NCT00572455 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00572455 about?
NCT00572455 is a clinical study titled "Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.". To evaluate the safety and efficacy of PF-04217329.
What is the current status of trial NCT00572455?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 318 participants. The study started on 2007-12-11. Estimated completion is 2009-06-26.
What interventions are being tested in trial NCT00572455?
The interventions under investigation include: PF-04217329 - Lowest Dose (DRUG), PF-04217329 - Low Dose (DRUG), PF-04217329 - Middle Dose (DRUG), PF-04217329 - High Middle Dose (DRUG), PF-04217329 - High Dose (DRUG).
Who is sponsoring clinical trial NCT00572455?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00572455's enrollment target sits among peer trials
318 153rd of 2000 higher than 1,846 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05488340 · 318 participants · Phase 2
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
- NCT05675735 · 318 participants · NA
Leveraging Regulatory Flexibility for Methadone Take-Home Dosing to Improve Retention in Treatment for Opioid Use Disorder
- NCT05895786 · 318 participants · Phase 3
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
- NCT06051617 · 318 participants · Phase 3
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI